Literature DB >> 29912591

Optical coherence tomography (OCT) study in Argentinean Huntington's disease patients.

Emilia Gatto1,2, Virginia Parisi1, Gabriel Persi1, Estela Fernandez Rey3, Martin Cesarini3, José Luis Etcheverry3, Pablo Rivera3, Ferdinando Squitieri4.   

Abstract

BACKGROUND: Huntington's disease (HD) is a genetic, rare and progressive neurodegenerative disorder that causes motor and cognitive impairment in midlife patients. Although retinal damage was observed in animal HD models and in patients with other neurodegenerative diseases, we still need confirmation of impairment in HD patients. Optical coherence tomography (OCT) is a non-invasive methodology that analyses the retinal nerve fibre layers (RNFL) and could reflect processes of neurodegeneration.
METHODS: A cross-sectional study with 14 HD patients who underwent a spectral domain OCT. Results were compared with a control group. Demographic data were also obtained.
RESULTS: Temporal and superior RNFL sectors in HD showed a significant RNFL thinning compared with a control group. However, no differences were identified in mean total RNFL thickness between HD patients and controls.
CONCLUSIONS: OCT is a rapid and non-invasive technique that can be investigated in larger cohorts of patients to assess its potential role as a biomarker in HD patients.

Entities:  

Keywords:  Huntington; Optical coherence tomography; biomarkers; neurodegenerative; retina

Mesh:

Substances:

Year:  2018        PMID: 29912591     DOI: 10.1080/00207454.2018.1489807

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  7 in total

1.  Huntington's disease and neurovascular structure of retina.

Authors:  Elahe Amini; Mehdi Moghaddasi; Seyed Amir Hassan Habibi; Zahra Azad; Shahnaz Miri; Naveed Nilforushan; Reza Mirshahi; Esther Cubo; Nahid Mohammadzadeh; Mohammad Rohani
Journal:  Neurol Sci       Date:  2022-06-30       Impact factor: 3.830

Review 2.  An Eye on Movement Disorders.

Authors:  Duncan Wilson; Mark Hallett; Tim Anderson
Journal:  Mov Disord Clin Pract       Date:  2021-08-10

Review 3.  Optical Coherence Tomography Angiography in Neurodegenerative Diseases: A Review.

Authors:  Georgios Tsokolas; Konstantinos T Tsaousis; Vasilios F Diakonis; Artemis Matsou; Straton Tyradellis
Journal:  Eye Brain       Date:  2020-07-14

4.  Structural Abnormalities of the Optic Nerve and Retina in Huntington's Disease Pre-Clinical and Clinical Settings.

Authors:  Iwona Mazur-Michałek; Katarzyna Kowalska; Daniel Zielonka; Marta Leśniczak-Staszak; Paulina Pietras; Witold Szaflarski; Mark Isalan; Michal Mielcarek
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 5.  Past, present and future role of retinal imaging in neurodegenerative disease.

Authors:  Amir H Kashani; Samuel Asanad; Jane W Chan; Maxwell B Singer; Jiong Zhang; Mona Sharifi; Maziyar M Khansari; Farzan Abdolahi; Yonggang Shi; Alessandro Biffi; Helena Chui; John M Ringman
Journal:  Prog Retin Eye Res       Date:  2021-01-15       Impact factor: 19.704

6.  No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onset.

Authors:  Rahel Dominique Schmid; Jana Remlinger; Mathias Abegg; Robert Hoepner; Rainer Hoffmann; Carsten Lukas; Carsten Saft; Anke Salmen
Journal:  Brain Behav       Date:  2022-05-05       Impact factor: 3.405

7.  Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1.

Authors:  Ricardo Mouro Pinto; Larissa Arning; James V Giordano; Pedram Razghandi; Marissa A Andrew; Tammy Gillis; Kevin Correia; Jayalakshmi S Mysore; Debora-M Grote Urtubey; Constanze R Parwez; Sarah M von Hein; H Brent Clark; Huu Phuc Nguyen; Eckart Förster; Allison Beller; Suman Jayadaev; C Dirk Keene; Thomas D Bird; Diane Lucente; Jean-Paul Vonsattel; Harry Orr; Carsten Saft; Elisabeth Petrasch-Parwez; Vanessa C Wheeler
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.